Serina Therapeutics (NYSE American: SER) is standing out in the biotech world for its push to simplify Parkinson’s care, moving from several daily pills to a once-weekly injection—a mission led by CEO Steven Ledger, who appears front and center in the company’s recent video announcement. In the video, Ledger articulates Serina’s core philosophy: “Our technology is designed to get into that [therapeutic] window quickly and to stay in that window for a week and with a single subcutaneous injection.”
Steven Ledger’s Vision
Steven Ledger, who took the helm as CEO in March 2024 after notable experience in finance and biotech leadership, is focused on practical problem-solving for longstanding drug delivery challenges in neurodegenerative diseases. Ledger emphasizes the shortcomings of oral levodopa—while it may initially work well with a twice-daily routine, by year five patients are often forced to take it up to eight times daily, with inevitable “drop-outs” from the effective range, especially overnight.
Breaking Through in Parkinson’s
Serina’s once-weekly subcutaneous injection seeks to “replace the burden of multiple daily doses” by maintaining steady therapeutic levels—what Ledger refers to as keeping therapies in the crucial “sweet spot” for maximum efficacy. This approach is powered by the company’s POZ platform, promising a new level of symptom control and quality of life for those affected by advanced Parkinson’s disease.
Regulatory and Market Traction
The company’s momentum is palpable following recent FDA support for its clinical plan and a ~50% stock surge, signaling investor confidence in both the platform technology and Ledger’s leadership. As clinical trials ramp up and Ledger continues to champion innovations targeting the “therapeutic window,” Serina Therapeutics is fast becoming a biotech name to watch—especially for patients, physicians, and Wall Street alike.
Sources
- https://www.youtube.com/watch?v=vwx4BVOphMg
- https://serinatherapeutics.com/team/
- https://www.wsj.com/market-data/quotes/SER/company-people/executive-profile/71770901
- https://investors.serinatherapeutics.com/news/news-details/2025/Serina-Therapeutics-to-Present-at-FORCE-Family-Office-Investor-Webinar-on-June-26-2025/default.aspx
- https://simplywall.st/stocks/us/pharmaceuticals-biotech/nysemkt-ser/serina-therapeutics/management
- https://www.stocktitan.net/news/SER/serina-therapeutics-to-present-at-force-family-office-investor-6olwknlab217.html
- https://www.stocktitan.net/news/SER/serina-therapeutics-to-present-at-the-btig-virtual-biotechnology-wpzpk1x5yjyp.html
- https://prismmarketview.com/serina-therapeutics-surges-28-premarket-after-fda-clears-path-for-registrational-trial-in-parkinsons/
- https://parkinsonsnewstoday.com/news/serina-using-5m-funding-develop-ser-252-advanced-parkinsons/
- https://www.bloomberg.com/profile/person/4960505
- https://fintool.com/app/research/companies/SER/people/steve-ledger
- https://www.investing.com/news/company-news/serina-therapeutics-appoints-new-ceo-with-strategic-goals-93CH-3614490
- https://www.imdb.com/title/tt0758752/quotes/?item=qt2336977
- https://news.va.gov/138326/va-secretary-doug-collins-veterans-benefits/
